DIM.PA PAR
Sartorius Stedim Biotech S.A.
1W: -2.0%
1M: +4.8%
3M: +16.1%
YTD: +16.6%
1Y: +19.0%
3Y: -21.6%
5Y: -60.4%
€208.20 ($234.30)
+2.00 (+0.97%)
Weekly Expected Move ±4.7%
€189
€198
€208
€218
€228
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$539M
-33.9% ▼
5Y CAGR: +5.3%
Capital Expenditures
$393M
-15.7% ▼
5Y CAGR: +19.8%
Free Cash Flow
$145M
-69.4% ▼
5Y CAGR: -10.8%
Dividends Paid
$67M
+0.0% ▲
Buybacks
$0
+100.0% ▲
Net Change in Cash
-$253M
-145.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $647M | $1.1B | $310M | $219M | $266M |
| Depreciation & Amort. | $142M | $182M | $238M | $302M | $318M |
| Stock-Based Comp. | $900K | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$146M | -$351M | $191M | $251M | -$25M |
| Other Non-Cash Items | $53M | -$348M | -$108M | $43M | -$20M |
| Operating Cash Flow | $696M | $612M | $630M | $815M | $539M |
| — Investing Activities — | |||||
| Capital Expenditures | -$324M | -$431M | -$474M | -$340M | -$393M |
| Acquisitions (Net) | -$142M | -$516M | -$2.2B | $0 | $0 |
| Investment Purchases | -$324M | $0 | $0 | -$100K | -$4M |
| Investment Sales | $324M | $0 | $0 | $0 | $0 |
| Other Investing | $432K | -$11M | -$8M | -$100K | $0 |
| Investing Cash Flow | -$465M | -$958M | -$2.7B | -$340M | -$398M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$5M | $392M | $2.3B | -$862M | -$321M |
| Stock Repurchased | $0 | -$3M | $0 | -$2M | $0 |
| Dividends Paid | -$63M | -$116M | -$133M | -$67M | -$67M |
| Other Financing | -$10M | -$52M | -$205M | -$178M | -$900K |
| Financing Cash Flow | -$72M | $221M | $2.0B | $85M | -$389M |
| Net Change in Cash | $164M | -$116M | $10M | $562M | -$253M |
| Cash End of Period | $224M | $107M | $117M | $679M | $426M |
| Free Cash Flow | $372M | $182M | $156M | $475M | $145M |